Denisa Weis,Liangguang L. Lin,Huilun H. Wang,Zexin Jason Li,Katarina Kusikova,Peter Ciznar,Hermann M. Wolf,Alexander Leiss-Piller,Zhihong Wang,Xiaoqiong Wei,Serge Weis,Katarina Skalicka,Gabriela Hrckova,Lubos Danisovic,Andrea Soltysova,Tingxuan T. Yang,Rene Gunther Feichtinger,Johannes A. Mayr,Ling Qi

Abstract:Suppressor of lin-12-like-HMG-CoA reductase degradation 1 (SEL1L-HRD1) ER-associated degradation (ERAD) plays a critical role in many physiological processes in mice, including immunity, water homeostasis, and energy metabolism; however, its relevance and importance in humans remain unclear, as no disease variant has been identified. Here, we report a biallelic SEL1L variant (p. Cys141Tyr) in 5 patients from a consanguineous Slovakian family. These patients presented with not only ERAD-associated neurodevelopmental disorders with onset in infancy (ENDI) syndromes, but infantile-onset agammaglobulinemia with no mature B cells, resulting in frequent infections and early death. This variant disrupted the formation of a disulfide bond in the luminal fibronectin II domain of SEL1L, largely abolishing the function of the SEL1L-HRD1 ERAD complex in part via proteasomal-mediated self destruction by HRD1. This study reports a disease entity termed ENDI-agammaglobulinemia (ENDI-A) syndrome and establishes an inverse correlation between SEL1L-HRD1 ERAD functionality and disease severity in humans.

Biallelic Cys141Tyr Variant of SEL1L is Associated with Neurodevelopmental Disorders, Agammaglobulinemia, and Premature Death.